Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRD 5

Drug Profile

CRD 5

Alternative Names: CRD5

Latest Information Update: 11 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Liponex
  • Developer Liponex; University of Ottawa Heart Institute
  • Class Antihyperlipidaemics
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Dyslipidaemias

Most Recent Events

  • 20 Jul 2007 CRD 5 is available for licensing worldwide (http://www.liponex.ca)
  • 18 Jul 2007 Preclinical trials in Dyslipidaemias in Canada (PO)
  • 13 Apr 2007 Results from a phase I/II clinical trial in patients with Dyslipidaemia added to the adverse events and Hyperlipidaemia therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top